PER 0.00% 8.0¢ percheron therapeutics limited

http://www.reuters.com/article/pressRelease/idUS154656+08-Sep-200...

  1. 75 Posts.
    http://www.reuters.com/article/pressRelease/idUS154656+08-Sep-2009+BW20090908
    Teva will present data on the effect of COPAXONE® on the Multiple Sclerosis
    Severity Score (MSSS) from the longest ongoing prospective study of an
    immunomodulatory therapy in RRMS. In addition, Teva and Active Biotech (NASDAQ
    OMX NORDIC: ACTI) will present data on laquinimod, its investigational oral,
    once-daily, immunomodulating compound being developed for the treatment of RRMS.
    New data on ATL/TV1102, a second generation antisense inhibitor of CD49d, a
    subunit of VLA-4, for the treatment of RRMS patients, will be presented as well.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
0.000(0.00%)
Mkt cap ! $72.12M
Open High Low Value Volume
7.9¢ 8.0¢ 7.9¢ $12.63K 158.7K

Buyers (Bids)

No. Vol. Price($)
2 66500 7.6¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 273231 2
View Market Depth
Last trade - 15.26pm 19/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.